Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Direct Plan - Growth Plan

Add To Compare

previously known as Reliance Pharma Dir Gr until

NAV on December 05, 2022
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 4,786 cr
Turnover Ratio 38.42%
Expense Ratio 1.05%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: -0.70%
  • 1Y: -1.88%
  • 3M: 6.03%
  • 3Y: 25.51%
  • 6M: 10.87%
  • 5Y: 17.22%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 17 years) Kinjal Desai (Since over 4 years)
ISIN INF204K01I50
Fund Family Nippon India
P/E Ratio 33.13
P/B Ratio 4.45
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 4.39
Beta 0.92
R-Squared 96.78
Info Ratio 0.99
Tracking Err 4.09
Sortino 2.268
Sharpe 0.997
Std Dev 20.862
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.

You will not receive any dividends. Your investments will get the largest benefit of compounding.

View Factsheet

-
Best Sector Healthcare Funds
NAME LATEST
NAV
RETURNS
1y    
FUND
ASSETS
Expense
RATIO
RISK
254.242 3.95% 1,728 cr 1.06% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon India